Abstract
Aims—Interleukin 6 (IL-6) is produced by some renal carcinoma cell lines in vitro. This might be biologically important because IL-6 is a cytokine of particular interest, owing to its involvement in the growth of renal cell carcinoma. In this study, the expression of IL-6 protein in tissue samples from primary renal cell carcinoma was analysed, and then its clinical importance was examined.
Methods—The distribution of IL-6 in renal cell carcinoma was examined by means of an immunohistochemical method in 47 untreated primary renal cell carcinoma samples. The search for a significant difference between histological patterns, Furhman's grading system, TNM classification, and IL-6 protein expression was carried out.
Results—Immunohistochemistry demonstrated that IL-6 is expressed in 70% of primary tumours. There was no significant difference in the tumour size and grade between renal cell carcinomas with or without IL-6 expression. However, a relatively large number of high grade tumours expressed IL-6.
Conclusion—The importance of IL-6 expression with regard to tumour size/local growth is questionable because IL-6 has been correlated with the development of metastatic disease. These data suggest that the production of IL-6 could exert a growth inhibitory effect on primary renal cell carcinoma.
Key Words: interleukin 6 • renal cell carcinoma • immunohistochemistry
Full Text
The Full Text of this article is available as a PDF (119.1 KB).
Figure 1 Interleukin 6 (IL-6) specific immunostaining of clear cell carcinoma (original magnification x400).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun 15;52(12):3317–3322. [PubMed] [Google Scholar]
- Costes V., Liautard J., Picot M. C., Robert M., Lequeux N., Brochier J., Baldet P., Rossi J. F. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol. 1997 Oct;50(10):835–840. doi: 10.1136/jcp.50.10.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fuhrman S. A., Lasky L. C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982 Oct;6(7):655–663. doi: 10.1097/00000478-198210000-00007. [DOI] [PubMed] [Google Scholar]
- Koo A. S., Armstrong C., Bochner B., Shimabukuro T., Tso C. L., deKernion J. B., Belldegrum A. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992;35(2):97–105. doi: 10.1007/BF01741856. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lagneaux L., Delforge A., Dorval C., Bron D., Stryckmans P. Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production. Blood. 1993 Oct 15;82(8):2379–2385. [PubMed] [Google Scholar]
- Lotem J., Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood. 1992 Oct 1;80(7):1750–1757. [PubMed] [Google Scholar]
- Lu C., Vickers M. F., Kerbel R. S. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9215–9219. doi: 10.1073/pnas.89.19.9215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989 Jul 3;250(2):607–610. doi: 10.1016/0014-5793(89)80805-1. [DOI] [PubMed] [Google Scholar]
- Paule B., Clerc D., Rudant C., Coulombel C., Bonhomme-Faivre L., Quillard J., Bisson M. Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Hum Pathol. 1998 Apr;29(4):421–424. doi: 10.1016/s0046-8177(98)90128-9. [DOI] [PubMed] [Google Scholar]
- Takenawa J., Kaneko Y., Fukumoto M., Fukatsu A., Hirano T., Fukuyama H., Nakayama H., Fujita J., Yoshida O. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst. 1991 Nov 20;83(22):1668–1672. doi: 10.1093/jnci/83.22.1668. [DOI] [PubMed] [Google Scholar]
- Tsukamoto T., Kumamoto Y., Miyao N., Masumori N., Takahashi A., Yanase M. Interleukin-6 in renal cell carcinoma. J Urol. 1992 Dec;148(6):1778–1782. doi: 10.1016/s0022-5347(17)37026-x. [DOI] [PubMed] [Google Scholar]
- Weiss L. M., Gelb A. B., Medeiros L. J. Adult renal epithelial neoplasms. Am J Clin Pathol. 1995 May;103(5):624–635. doi: 10.1093/ajcp/103.5.624. [DOI] [PubMed] [Google Scholar]